Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Allocation: Randomized, Interventional Model: Parallel Assignment, Masking: Quadruple
Primary outcome measures:
Annualized Relapse Rate (ARR)
946 patients received ofatumumab and 936 teriflunomide; The mean follow-up time was 1.6 years. The annual recurrence rates in the ofatumumab and teriflunomide groups were 0.10 and 0.25, respectively (P<0.001). In the pooled studies, the percentage of patients with confirmed disability worsening at 3 months was 10.9% on ofatumumab and 15.0% on teriflunomide …